Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHA:603882)
China · Delayed Price · Currency is CNY 32.16
+0.31 (0.97%)
Feb 4, 2026, 3:00 PM CST
SHA:603882 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 5,546 | 6,627 | 7,726 | 14,529 | 11,304 | 7,870 |
Other Revenue | 562.98 | 562.98 | 813.43 | 946.76 | 639.52 | 373.96 |
| 6,109 | 7,190 | 8,540 | 15,476 | 11,943 | 8,244 | |
Revenue Growth (YoY) | -22.17% | -15.81% | -44.82% | 29.58% | 44.88% | 56.45% |
Cost of Revenue | 4,121 | 4,807 | 5,425 | 8,802 | 6,295 | 4,395 |
Gross Profit | 1,988 | 2,383 | 3,115 | 6,674 | 5,648 | 3,849 |
Selling, General & Admin | 1,441 | 1,529 | 1,730 | 2,506 | 2,323 | 1,613 |
Research & Development | 341.26 | 400.47 | 467.14 | 632.62 | 517.93 | 397.17 |
Other Operating Expenses | 44.03 | 15.91 | 14.91 | 14.75 | 11.71 | 6.93 |
Operating Expenses | 2,369 | 2,564 | 2,700 | 3,409 | 2,924 | 2,064 |
Operating Income | -381.18 | -180.92 | 414.93 | 3,266 | 2,724 | 1,785 |
Interest Expense | -15.83 | -18.43 | -20.39 | -23.65 | -27.55 | -29.26 |
Interest & Investment Income | 24.6 | 23.48 | 288.36 | 30.4 | 21.53 | 13.76 |
Currency Exchange Gain (Loss) | 0.21 | 0.2 | -0.6 | 9.14 | -1.46 | -0.2 |
Other Non Operating Income (Expenses) | 11.73 | -2.7 | -2.95 | -3.91 | -2.54 | -2.03 |
EBT Excluding Unusual Items | -360.48 | -178.37 | 679.35 | 3,278 | 2,714 | 1,767 |
Gain (Loss) on Sale of Investments | -135.7 | -140.82 | - | -10.8 | -7.29 | -18.66 |
Gain (Loss) on Sale of Assets | -146.88 | -143.59 | -7.57 | 2.97 | -10.11 | 1.43 |
Asset Writedown | -0.35 | - | - | - | - | - |
Other Unusual Items | 26.71 | 24.14 | 68.51 | 50.64 | 50.87 | 60.42 |
Pretax Income | -616.71 | -438.65 | 740.29 | 3,321 | 2,748 | 1,810 |
Income Tax Expense | -29.34 | -23.94 | 103.38 | 475.72 | 384.05 | 237.04 |
Earnings From Continuing Operations | -587.37 | -414.7 | 636.91 | 2,845 | 2,364 | 1,573 |
Minority Interest in Earnings | 32.68 | 33.46 | 6.47 | -90.22 | -143.87 | -63.73 |
Net Income | -554.69 | -381.24 | 643.38 | 2,755 | 2,220 | 1,510 |
Net Income to Common | -554.69 | -381.24 | 643.38 | 2,755 | 2,220 | 1,510 |
Net Income Growth | - | - | -76.64% | 24.11% | 47.02% | 275.24% |
Shares Outstanding (Basic) | 464 | 465 | 466 | 466 | 462 | 459 |
Shares Outstanding (Diluted) | 464 | 465 | 466 | 467 | 466 | 462 |
Shares Change (YoY) | -0.56% | -0.28% | -0.15% | 0.13% | 1.00% | 0.98% |
EPS (Basic) | -1.19 | -0.82 | 1.38 | 5.91 | 4.80 | 3.29 |
EPS (Diluted) | -1.19 | -0.82 | 1.38 | 5.90 | 4.76 | 3.27 |
EPS Growth | - | - | -76.61% | 23.95% | 45.57% | 271.59% |
Free Cash Flow | 875.3 | 459.99 | 516.07 | 1,107 | 1,136 | 972.45 |
Free Cash Flow Per Share | 1.89 | 0.99 | 1.11 | 2.37 | 2.44 | 2.11 |
Dividend Per Share | 0.880 | 0.880 | 0.880 | 1.780 | 1.280 | 0.329 |
Dividend Growth | - | - | -50.56% | 39.06% | 289.06% | 141.91% |
Gross Margin | 32.54% | 33.15% | 36.48% | 43.13% | 47.29% | 46.69% |
Operating Margin | -6.24% | -2.52% | 4.86% | 21.10% | 22.81% | 21.65% |
Profit Margin | -9.08% | -5.30% | 7.53% | 17.80% | 18.58% | 18.31% |
Free Cash Flow Margin | 14.33% | 6.40% | 6.04% | 7.16% | 9.51% | 11.80% |
EBITDA | 47.9 | 257.86 | 866.66 | 3,679 | 3,056 | 2,066 |
EBITDA Margin | 0.78% | 3.59% | 10.15% | 23.77% | 25.59% | 25.06% |
D&A For EBITDA | 429.08 | 438.78 | 451.73 | 412.85 | 331.56 | 280.85 |
EBIT | -381.18 | -180.92 | 414.93 | 3,266 | 2,724 | 1,785 |
EBIT Margin | -6.24% | -2.52% | 4.86% | 21.10% | 22.81% | 21.65% |
Effective Tax Rate | - | - | 13.96% | 14.33% | 13.98% | 13.09% |
Revenue as Reported | 6,109 | 7,190 | 8,540 | 15,476 | 11,943 | 8,244 |
Advertising Expenses | - | 0.76 | 2.16 | 3.29 | 3.16 | 2.71 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.